Nicole Junkermann on Why Patient Capital Matters in Tech

What patient capital means

Patient capital is a simple idea with deep consequences. It means money invested with a long time horizon and a genuine willingness to wait for results. Instead of pushing for a quick return, patient capital gives a company the room to do hard things properly. For Nicole Junkermann, this is not a slogan but a working method, and it shapes how she supports founders through NJF Capital.

The contrast is with capital that is in a hurry. Money that needs an answer quickly tends to push companies toward whatever shows results fastest, which is not always what builds the most value. Patient capital does the opposite. It accepts that the best outcomes in technology often take years, and it stays the course while they take shape. In that sense, patience is a kind of resource, as real as funding or talent.

Why good technology is slow

The technologies Nicole Junkermann cares most about share an awkward truth: they are slow to mature. Artificial intelligence applied to a serious problem, a biotech advance, a piece of deep technology, all of these take time to move from a promising idea to something reliable. The science has to be proven, the engineering has to be made robust, and the product has to earn the trust of the people who will depend on it.

None of that can be rushed without doing harm. A health tool released before it is ready can erode the very trust it needs. A deep technology company pushed to show results too soon can be forced to cut the corners that mattered. The slowness is not a flaw to be fixed. It is the natural pace of building things that are genuinely hard and genuinely worthwhile, a point explored further in the note on deep tech explained.

The unglamorous middle

Every ambitious company has a difficult middle stretch. The excitement of the early days has faded, the breakthrough has not yet arrived, and the work is mostly quiet, unglamorous progress. This is the phase where many promising companies struggle, not because the idea was wrong, but because the support ran out of patience before the work was done.

Patient capital exists precisely for this stretch. Nicole Junkermann sees real value in standing with founders through the middle years, when steadiness matters more than excitement. A backer who understands this can be the difference between a company that survives long enough to succeed and one that is forced to stop just before it would have come good. The middle is where patience earns its keep.

Patience and trust

There is a close link between patience and trust, and it runs in both directions. A patient backer earns the trust of founders, who know they will not be pushed into damaging short-term decisions. And patience gives companies the time to earn the trust of their own users, which in fields like health and finance is the foundation of everything.

Trust simply cannot be built quickly. People take time to rely on a new tool with their health or their money, and that reliance has to be earned through consistent, careful behaviour. Patient capital makes space for that slow building of trust, which is one reason it sits so naturally beside Nicole Junkermann's wider thinking about how to choose what to back, set out in the note on how she decides which technology to back.

What it gives founders

From a founder's point of view, patient capital changes what is possible. It allows a team to make the right decision rather than the fast one, to invest in quality that will pay off later, and to weather the inevitable setbacks without panic. It lets founders focus on the work instead of on a clock.

This is closely tied to Nicole Junkermann's belief in backing people, not just ideas, which she explores in the note on investing in founders. Patient capital is, in part, an act of confidence in a team. It says: I believe you can build something that lasts, and I am willing to give you the time to do it. For the right founders, that confidence is as valuable as the funding itself.

• Room to choose quality over speed.
• Freedom to weather setbacks without panic.
• Time to earn the trust of real users.
• Confidence that the work will be allowed to mature.

Patience in practice

It is worth saying that patience is not the same as passivity. A patient backer is still engaged, still asking hard questions, still helping where they can. The difference is the horizon. Patient capital combines genuine support in the present with a calm acceptance that the biggest results lie further out.

It also helps to be clear about what patient capital is not. It is not a tolerance for drift, and it is not an excuse to avoid hard questions. A patient backer still expects progress, still wants to see a team learning, and still cares about the path from idea to product. The patience is about the horizon, not about standards. Nicole Junkermann holds founders to a high bar precisely because she intends to support them for a long time, and a long partnership only works when both sides are honest about how the work is going.

That balance, active help with a long view, is at the heart of how Nicole Junkermann works with the companies she backs. It is also why her interests in artificial intelligence, biotech and deep technology fit her temperament so well. These are fields where patience is rewarded, and where the willingness to wait is itself a form of insight. To see how this connects to the wider picture, you can return to the work of Nicole Junkermann or read about her map of innovation.

Frequently asked questions